Lisavienna newsletter 2/2016 web

Connecting Life Sciences

Highlights 02/2016

Life Science City Vienna: Broad Expertise on Software

page 3

Innovation made in Vienna: Ottobock’s AxonHook and Kenevo

page 8

© Octapharma

© Octapharma/APA

Investing in Vienna Octapharma is a privately-owned global human protein manufacturer that follows a well-defined strategy for improving patients’ lives.

Currently, it is investing 13.5 million euros in the construction of a new lab and office building in Vienna. Octapharma employs almost 1,000 highly skilled employees in Austria and has a clear path for growth.

Headquartered in Switzerland, Octapharma is dedicated to the safe and optimal use of human proteins from plasma and cell lines. The biopharmaceutical company employs some 6,400 people around the globe to support the treatment of patients in critical care or suffering from coagulation and immune disorders.

In Vienna, Octapharma operates its largest manufacturing plant worldwide, including one

© Octapharma

of the most modern plasma fractionation facilities. The production plant meets GMP requirements and is FDA-approved.

75,000 m2 for innovation With a work force of some 1,000 people in Vienna, Octapharma is active in R&D, clinical research, manufacturing, quality control and international approval of drugs. The company’s 75,000 m2 site has been continuously extended and updated to increase production capacities and to adopt new technologies.

Octapharma started the construction work for a new R&D center in Vienna, as laboratories and office spaces grew too small for the corporate plasma-based R&D located here and subject-specific universities are close-by. The initial construction costs for the barrier-free, low-energy building add up to € 13.5 million.

It will house highly attractive workplaces for some 100 people in 13 labs and 39 offices. A new subway connection close to Octapharma’s plant will open soon.

Rewarding challenges In Vienna, plasma-derived products are being developed and manufactured. For example, the new Fibrinogen-concentrate is currently developed to be brought to the market, preclinical development also took place here.

Octapharma is hiring in order to develop more success stories and to significantly increase production capacities. Bring in your expertise in chemistry, pharmaceutical production and quality control. Outstanding opportunities are available for people that have the desire to make a difference in this world and to gain global experience. octapharma.at

Dear readers!

Vienna is Austria’s most important place for the life sciences – from research and teaching to the commercial biotech sector and the pharmaceutical and medical device industries.

Major investments such as those of Octapharma, which is featured in our newsletter cover, and worldrenowned innovations like the ones from Ottobock, which are presented at the back, recognize and reinforce Vienna’s outstanding position among the leading European innovation centers.

In addition, our scientific community enjoys an excellent reputation and is highly successful in attracting prestigious grants. In 2015, 80% of all ERC funds granted to researchers in the life sciences in Austria went to host organizations in Vienna. We are incredibly proud of this recognition.

Recent months have shown growing international interest in software in the life sciences due to the major economic potential linked to this interface.

Therefore, we are including an article on page three about a few IT companies based in Vienna. On page four and five, we update you about recent R&D highlights and commercial success stories. For an exciting account on regenerative medicine in Vienna, please check out page seven.

We hope you enjoy the reading and are inspired by the success stories we present. Please check out our extensive web resources at LISAvienna.at to find out more about life sciences in Vienna and do not hesitate to contact us personally. Our technology experts would welcome the opportunity to discuss support and funding opportunities in Vienna with you and can provide you with an overview on lab space available for rent, for example.

Starting-up and growing your business in Vienna pays off!

Peter Halwachs and Johannes Sarx LISAvienna Executive Board

LISAvienna – Connecting Life Sciences LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, it contributes to the advancement of life sciences in Vienna.

LISAvienna supports innovative biotech, pharmaceutical and medical technology companies in Vienna that develop and market new products, services and processes. The platform links these companies with development partners and key customers. As a central knowledge carrier, LISAvienna provides input for decisions to advance the life sciences in Vienna and contributes to positioning the city of Vienna as one of the leading European innovation centers.

Please visit our website www.LISAvienna.at to learn more about Vienna as a top location for life sciences!

Our Services Information & Consulting:

Tips and contacts relating to sponsorship, private financing options, lab space in Vienna, development partners, leading customers and internationalization

Networking & Matching:

Contacts for an improved exchange of experiences and knowledge transfer as well as contact with development partners, leading customers and investors worldwide

Expertise:

Life Sciences in Vienna at a Glance • 480 organizations • 35,730 employees • 9.9 billion euros revenues • 32,870 students • 4,800 publications Vienna offers an ideal environment for the development of novel ideas and technologies into thriving businesses. We invite you to profit from leading global life science companies, successful start-ups, world-renowned academic institutions and top-class hospitals when starting-up in Vienna. Tailored funding and support opportunities are available to make your visions come true!

Learn more about the life science city Vienna!

Download the Vienna Life Science Report at www.LISAvienna.at and be invited to order your free print copy at office@LISAvienna.at.

2

Analyses, background information, reports and studies relating to life sciences in Vienna

Marketing:

Electronic and printed news items from the field of life sciences in Vienna

10 times a year: LISAvienna e-Newsletter Stay updated on hottest news from the life science city Vienna!

Subscribe at www.lisavienna.at/en/e_newsletter

Life Science City Vienna:

Broad Expertise on Software

Vienna is Austria’s central meeting point for talent. In fact, no other city in the German speaking countries attracts more students than Vienna. This unique setting enables an innovative crossover of approaches to solve problems, novel ideas and technologies.

The multiple interfaces between the life sciences and IT provide a good example in this regard, resulting in an increasing stream of new products and services in Vienna.

Biotechnology, the pharmaceutical industry and the medical device sector all profit from making use of software knowhow. Indeed, the life sciences experience fundamental transformations not only on the technological level and through increasing knowledge about molecular characteristics, but also through the powers of algorithms and databases. The following companies provide you with an idea of the diversity of unmet needs successfully addressed in Vienna.

Agfa HealthCare Ges.m.b.H. is a pioneer in both patient-centered imaging technologies and diagnostic image enhancement as well as in administrative and medical workflow optimization in hospitals worldwide. contextflow GmbH uses advanced machine learning to analyze big medical image and text data. Their medical image search engine RadiologyExplorer instantly finds visually similar cases

Why Vienna?

as well as case relevant statistics, guidelines and references.

CVTec Cerebrovascular Technologies GmbH develops software for neurointerventionists. The first product is an occlusion rate measurement system. Blood flow analysis and risk assessment systems will follow.

Diagnosia Internetservices GmbH supports evidence-based decision making by providing medical professionals with up-to-date information on drug safety. The software suite can easily be integrated into hospital IT. Medexter Healthcare GmbH provides customized clinical decision support solutions for hospitals, research and teaching, or B2B integration.

Medical content packages as well as monitoring and reporting tools for use in clinical routine are also offered.

Medizinkraft Solutions GmbH provides a 3D sensor and special software for both the objective and contact-free measurement and the analysis of human mobility constraints linked to muscle and skeletal diseases. mySugr GmbH goes for app-based, all-around care for people with diabetes. mySugr’s Logbook is a registered risk class 1 medical device in the US and EU. Scanner, education and analysis tools facilitate life.

“

Markus Holzer, contextflow GmbH

Vienna combines talent, a good early stage start-up ecosystem and a growing health community that provides interaction and exchange of knowledge. With its central location in Europe and recent political support, it is becoming a hot spot for high-tech innovation!” © contextflow GmbH

Highlights 02/2016

piur imaging GmbH provides innovative tomographic ultrasound for safe and cost-effective vascular diagnostics. 3D vascular imaging is achieved by extending ultrasound devices with a tomography feature.

Platomics GmbH provides innovative software solutions for personalized medicine. A marketplace of > 5,000 certified apps each representing a specific gene test will revolutionize genetic testing.

NEW:

CSH - Com plexity Science Hu b Vienna

The CSH ho sts, educates , and inspire plex system s coms scientists w ho are dedica collect, hand ted to le, aggregat e, and make of big data in sense ways that ar e directly va for science an luable d society. Fo cus areas in smart cities, clude systemic ris ks, medical, ecological, an social, d economic systems. csh.ac.at

SCARLETRED Holding GmbH stands for next generation dermatology. The company supplies GCP compliant medical mobile Apps for objective real-time monitoring and analysis of skin disorders and drug effects.

TissueGnostics GmbH generates algorithms for tissue segmentation used in advanced tissue cytometry to provide solutions for high content and high throughput scanning and analysis of biological samples.

agfahealthcare.com cvtec.at diagnosia.com medexter.com medizinkraft.at mysugr.at piurimaging.com platomics.com radiology-explorer.eu scarletred.at tissuegnostics.com

3

ters ency fos g A s s e usin n Vienna Bndly innovatio ie y users user-fr chnolog cts put te l:

Bulletin d

proje leve lopment sciences and deve nded life h fu rc ly a w e e s e re Four n ady at th tage alre ce of center-s complian increase to n o ti a Gamific GmbH: ement • alysis ts e manag n atie proving th COPD p Im r fo ls igital too t mbH: D elopmen ecisions • dwh G duct Dev ro critical d P h lt a e H improve to rd of the a o b h cesses bH: Das ction pro TEC Gm and cal produ ti • EXPU u e c a Firmware iopharm GmbH: ng ts c u s during b d d e teeri ro hcare P dividualiz lt in a r e fo H g k oc e-tunin • Otto B g and fin ed trainin app-bas s rosthese of hand p

Boar

Evercyte Gmb on the developH and VTU Technology coll supplements ment of recombinant med aborate ia The first conj ointly develo ped recombi Factor 165 (V nant product, EGF 165), ha Vascular Endo s been launch thelial Growth Evercyte’s pr ed, and furth ecise and repr er targets are od uc in the pipelin ible in-vitro ce quality of each e. ll-based assa production ba ys guarantee tch. the high evercyte.com

Lexogen GmbH to upgrade kit based on users’ needs

Platomics GmbH to revolutionize genetic testing By offering a unique digital genetic testing platform called PlatoXTM, Platomics is speeding up the process of bringing the benefits of personalized medicine to the patients. Medical doctors profit from more than 5,000 certified apps each representing a specific gene test for the diagnosis of the most important known hereditary diseases.

Lexogen has successfully accommodated major advancements into its RiboCop rRNA Depletion kit for human, mouse and rat samples. The new protocol among others allows for low concentrated RNA and for processing samples in a 96-well plate format. lexogen.com

Platomics will also develop an innovative epigenetic-based diagnostic kit for the detection of thyroid cancer together with AIT and Diagnode. For this project, the consortium has been ranked first place among all Eurostars-2 projects that have been selected for funding recently. platomics.com

I

© Lexogen

Vienna

Zytoprote phase II c GmbH comple study wit h novel p tes enrollment in PD-prote eritonea c® is curr l dialysis ently bein II clinical tr g tested in fluid ial. 5 a

3 patients randomiz ed, double have bee Recently, n enrolled -blinded P Zytoprote at eight st c hase h a s also est MedUni V udy cente ablished a ienna in o rs in Austria “Christian rder to bo .

Doppler L ost bioma ab” togeth rker resea zytoprote er with c.com rch in perit oneal dialy sis.

ises uccessfully ra AFFiRiS AG s cing y equity finan € 10 million b ibed by

equally subscr tment has been lding The new inves tors, Santo Ho two major inves altungs rw Ve the company’s IG M e th d r, family office) an e new investo (Strüngmann in addition to th s, nd Fu IG M AG adviced bH. FCPG Affi Gm affiris.com

4

Get connected @

(@lifesciencevie)

Valneva

successfully completed a Phase II study for its Clostr idium difficile vaccine candidate

tive eting: Innova e M s s e in s u B Academia in Vienna LISAvienna ices made in Vienna The final results of the randomi zed, placebo-controlled, obs – Facts & Figures v e d l erverblind multi-center trial involving medica eveloping 500 subjects confirm rtner for co-d Life Science

ed the positive e pa initial phase II dataTa nna is a prim Academ nt eva ialearned about . le as thinten Valn e keds ente y totosu versity of Vie ra ni partnering agreeU cces al participants ic ar s ed in M m e ment for the phaseMIIIorstud se Th 0 eoveyr, of 20 in-offs and ing. One of withis e than th ne prog arly ram Thestcom . Several sp the most pr 33,0. 00 y has also devices. Mor al udenpan esed technologies tigic recently announced the the ts in w m io us life succ ne d fu scienessf nd so an ing ur ces ul ce ow alogen ion ne,erat Vien ly ble know-huniversities ispehig fied s on a European lev na of nces. edauchigh moreteyoung ates puri Zika vaccine candida theelav isaithlae European Resear s-on ex rieh: together, their 10,376 usingscits ientis FDA ha -EM lifend ts in ed id ch science em rove theAfieapp ov d Co Jap pr ane un s se ld than any cil. st up pl tHear oy other city in re Encephalitis platform ees (56% fe , a total of 54 life . Apart from Austthat male, 54% ria. Th , Valn researchers) is figeva rted strong rev- science researchers fro ure repo repres generated ents ughly enue growth andro m Vi 56 4,230 publ en ha pos % na itive EBITofDAallinstH1 d secured tio icacon uden ns firm th ing in e multimillion ts studyinthe peer-reviewe pany’s g thcom life sciences euro grants trend towards EBIT d jour nals in e by the end DA break-ev in Au 2014. In en.stria in 2014 the framew of 2014. or

28 of them (28 out of k of this re 30 Austrian went to port, four un scientists ba universities sities provid iversed in one and applied ed informat of the instit versities re un iion about th lo ut ported a to cated at the es eir life sc ien tal of 59,1 Vienna Bioc ce budget.

66 life en science stud Ac ter (VBC). In cording to total, the Vi ents). In 2014 this, they spent 792 ennese gran , around 3,40 million euro t winners ac students gr 0 s in 2014. count for 81% of aduated in In total, the univers all Austrian Vienna, esta itie s educated life science blishing the long grants, unde ERC some 31,6 -term basis st ud 12 rlin ents in the for further gr ing the hig life science h competitive owth in the sector ness and at s in 2014 an . Vienna als accounted tractiveness d o leads the for 3,123 of the local with respec field graduates. demic scen acat to scientifi Study programs co e on an inter c quality wh ver a broa national lev measured on en d range of el. the basis of jects, ranging subregor s’ G ncere-re from human viewed ists iepe publications c S f o Re and veterin y ic . aInde20 no s m14, Vien wned univ y h m p ary ed d c ici n ne A ersities na a , biology an searustrianpu d biotechn gy (GM-bI)ased re-evel-The capita iolo blla ishned ology to t Bar om the A chers la fr medical engi -d l’s o ou co ts P c nd re is r e sc 4, g v 80 ien u neering. tific base lie lecpe Biolo ceopa ayr mbH ha0 life sci- issiofivne univers s in its oenf M rs as c s Glas na / Michlm firilisttieor ities. The lar © LISAvien em Institute t auctheor nc gest one is Core Fa s.eThis r isc55 Mendel s te n % re e th e o of iv e ve Un all s lu iartic Applied un ue:reFported by the non-inva rsity of Vienna, founde nna Bio niqles iversities r42 Ausd back in 13 trian opy tech at the Vie In the sam 65. allows fo i) io microscresearch inorgga(Fniz B Vienna is ho w e at e ye n ar ns , a th ac e Medical Un l g tiv me to two ap a a e ic in life ri n oped im th a e sc g h ien n ces. Clearly the mec plied univers iversity of Vienna wa In 2014, toge ities. , scatte s also establ ther they ac pping of this outitp ished as a M et-quires signifi3ca Brillouin counted for onutbre cal Faculty edilu d Dntmaand onh o n s a go 1, re n st 260 ing ud o of a ti en public fundthe the Univers ts and 300 gr lls wit ity of Vienna investiga espe aduates. Th ciainllyg c Since 2004 ase research ter – and for ing – . e Universigrow f ty o , e of th in s Ap e th im ie M e pl ill ed rt ied Science life sc ical Univers ien e.ces fam can benve prope s Technikum enc ity of Vidth ry otim enna has be e-consitum W ien is fluoresc the largest en an autono a thousa Austrian tech tion w h ing and costly. In mous unive a in ter than 2014, caoto b nical applied m Bo rs tal of 16 Vi ity. th universitie in r ve e unirs en v ity e na-based ins s join forces . W ith resp ect to the tituin m first time tions gave full pa olec The res biology at th life science ear r d „Bithosi chula fiel rticulars with e e th gna M em ax l Pro atic ces F. Perutz La respect to sinasg”isinofthe Digital Sa s, emph their life scien bothe ratoAIT its bachelor fety & Security De ment of (MFPL) at th riesAustri ce budget: man partand aste e VBC. In 17 a total of 95 Ins r titu st te ud of y Tec prograhno 65, the acad 7 million euros wa ms log cen liesy con scene was emic of on the development on bi s available. omtra calys edtes ana l en enlarged by new automatic iis gi of ne EE er G sig ing nal , s.

Em e-healtCo nne press Maria h an this unit and profit from Theresa wh expert d ct reto ise to co-develo newa tech ble o founded its p no new logisol es utio – allnsoffor the Univers High intern thepi sy eselep dia gno ityveof Veterinary M hig stics, mobile long-term EE ational com G, hly inte inn nsi ovacare tiv e an edicine as th and petitivenes d neu ra ros pi urg dly ery e first veterin evol! ving field The excelle s medicine ed s with a hig ary nce of Vien need for qu ucational es ww h nese scien alified empl tablishw.e nce is also refle tists .co men oyees and int m | t invis ww German-spe w.a th cted in the it.ac.at e erdisciplinary kn aking world fact that th owledge. Th . In 1815, TU ey are highly succ e University enna was es Viessful in ra of Applied Science tablished an ising third-p s FH Campu d finally, in 18 funds. Here arty s Vienna on the Univers 72 , 16 institut , ot the ity of Natura her hand is ions provided th l e largest Au Resources numbers. To their Lifems and strian applied gethulat Sciences (B to train medical tea er ors university. W theyhelp d sim OKU) was ini raise chil ke d ith a in th to Convincinglyoflifeli tia e field of life tal undno 224 million ted, which erw has a sciences, euro y medicine it educates strong focu c seminerg iatri exenc ternal finan its students s on applied for critical situations in ped cin the areas for te ter bi ch Cen ono the lo with n of biogy en . The scientifi gineering, bi In collaboratio c relevance oinformatics highly realistic conditions. of the and molecula Medical the of ring bi inee ot Eng l ec r hnology, am medica ong others.

Medical Physics and Bio y SIMCharacpan com 16 se nne ne Vie w new ERC grants ha University of Vienna, the ve been awarde Vi researchers in child simulator to date.enna d to Vienna-bas Rest of Aust eloped the most realistic the life science ed ria ters has dev s in 2015 as co 40% (7,855) 4 grants in the re mpared to 60% (11,975 st of Austria. ) 45% (3,963 simcharacters.com ) 55% (4,816) 44% (26,29 4) 56% (32,87 Re2)st of Au 19st %ria (13 : 4) Vien81 na%: 16 (54)

valneva.com

loped gy deve lo o n h c py te er icrosco New m ienna Biocent V e h at t

Connect to expert ise in EEG at the A IT Austrian Institut e of Technology

to launch “Paul”, SIMCharacters GmbH t advanced highthe smallest and mos in the world end patient simulator

Vienna in Au

Vienna: Austr life sciences ia’s best place for the

stria

Employees Publications Students ERC-Grants

Figure 19: Nu

mber of life

tions

science emplo

yees, publica

tions, studen

ts (2014) an

© SIMCharacters

More news For more news please visit our website www.LISAvienna.at

Highlights 02/2016

d ERC grants

Your news placed here

(until 2014)

in respec Cativ lcuely lati

on: byLIS Avi ac enna ad

embas ed on ic ins data availab titu-

le at erc.europa.e u

37

Vienna-based organizations are invited to e-mail news and press releases to news@LISAvienna.at to contribute to LISAvienna’s digital and print media.

5

Business Location Vienna.

The ideal location provides the best foundation. The Vienna Business Agency therefore supports relocating and expanding companies.

Apply now for your funding at viennabusinessagency.at Vienna supports economy.

Meet LISAvienna • The European Forum for Industrial Biotechnology and the Bioeconomy Glasgow, October 18-20, 2016

50.000 Euro aws Temporary Management

• BIO-Europe 2016 Cologne, November 7-9, 2016

Financing of complementary management expertise www.awsg.at/maz

• ESIB 2016 – The European Summit of Industrial Biotechnology Graz, November 14-16, 2016 • Medica 2016 Düsseldorf, November 14-17, 2016

800.000 Euro aws Seedfinancing Financing the start-up phase of life science companies www.seedfinancing.at

• PCT 2016 – Partnerships in Clinical Trials Europe Vienna, November 16-17, 2016 • Arab Health 2017 Dubai, January 30 – February 2, 2017 • HiMSS 2017 – Annual Conference and Exhibition Orlando, February 19–23, 2017

200.000 Euro aws PreSeed Financing the pre-start phase www.preseed.at

• BIO-Europe Spring 2017 Barcelona, March 19-22, 2017

We bring Life Sciences to Life www.lifescienceaustria.at

• conhIT – Connecting Healthcare IT Berlin, April 25-27, 2017

in cooperation with:

Hidden Champion: Translational Research for Trauma Patients The Austrian Workers’ Compensation Board, AUVA, is the Austrian Social Insurance for occupational risks for more than 3.3 million employees and 1.4 million school and college students. It is financed mainly by contributions paid by employers. Its legal duties are the prevention of occupational accidents and diseases, occupational medical care, first aid for occupational accidents, post traumatic treatment, rehabilitation, financial compensation and research.

Translational research that saves lives In 1980, the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology (LBI-Trauma) was founded and became the core of AUVA’s trauma research center. The Ludwig Boltzmann Gesellschaft (LBG) has played a central role in establishing trauma research in Vienna. LBG is an independent research institution in Austria with 18 research institutes that address relevant questions in the field of health sciences and the humanities.

LBG promotes translational topics and open innovation in science in Austria.

Strong network on tissue regeneration Tissue regeneration is one of the trauma center’s core research areas when it comes to the codevelopment of new drugs and medical products.

Strong ties have, for example, been established with Baxter in the course of the joint development of its fibrin sealant and related tools and while codeveloping Hemopatch for bleeding control. To allow for an improved exchange of knowledge, the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology has founded the Austrian Cluster for Tissue Regeneration in 2006 together with major Viennese universities like BOKU, MedUni Vienna and TU Wien as well as with various commercial partners. The non-profit spin-off company Trauma Care Consult GmbH supports research a LBI-Trauma and facilitates cooperation with industry since 1998. Strong experience in

Repuls Lichtmedizintechnik GmbH applies the most modern LED technology with cold red light for reduction of inflammation and pain and improving quality of life.

SCARLETRED Holding GmbH supplies GCP compliant medical mobile Apps for objective realtime monitoring and analysis of skin disorders and drug effects.

collaborative research in large consortia has also been gathered in the context of >10 EU-funded endeavors including in the European Institute of Excellence for Tissue Engineering and Regenerative Medicine “Expertissues” or the current “Biodesign” and “Arrest Blindness” projects.

TAmiRNA GmbH discovers and validates microRNA biomarkers to provide diagnostic solutions to patients with serious aging-related illnesses.

To connect to this extensive expertise in intensive care and tissue regeneration from cartilage & ligament, neuroregeneration, wound healing and bone regeneration, please contact Heinz Redl at office@trauma.lbg.ac.at or via phone at +43-(0)59393-41961.

Expertise advances innovative companies

auva.at lbg.ac.at trauma.lbg.ac.at traumacareconsult.com aposcience.com braincon.com evercyte.com lithoz.com repuls.at scarletred.at tamirna.com

LBI-Trauma’s ever-growing network of research institutes, companies and hospitals also includes several small and medium-sized companies based in Vienna. The following examples show the broad spectrum of topics addressed by these commercial partners: Aposcience AG is developing drugs for regenerative medicine based on the secretomes of white blood cells isolated from peripheral blood.

Bio-Products & Bio-Engineering AG specializes in R&D for biologics.

Braincon Handels-GmbH has developed expertise in digital radiology including tools and software for bone microarchitecture assessment.

Evercyte GmbH has set out to provide human cell lines and iPS cells for cell-based assays, as production hosts or as predictive in-vitro models.

Lithoz GmbH specializes in the development and production of ceramic materials and additive manufacturing systems (3D printing).

Why Vienna? © Heinz Redl

Over the past 40 years, the Center for Traumatology Research in AUVA’s Lorenz Boehler Hospital in Vienna has become an outstanding unit for up-to-date medical research. It focuses on improving diagnostic and therapeutic measures in emergency medicine and trauma surgery. Its main projects are in the fields of intensive care, tissue regeneration and center on special scientific approaches including imaging and the development of biomaterials. Today, a total of >90 highly-skilled people gather at Lorenz Boehler Hospital and at additional locations every day to conduct research for the benefit of patients suffering the consequences of severe accidents.

Heinz Redl, Head of LBI-Trauma

“

The LBI-Trauma in Vienna has a long tradition of cooperation with Austrian and international companies in the preclinical and clinical setting. Multidisciplinary expertise organized in several competence centers is available to co-develop innovative solutions for trauma patients.”

7

Innovation made in Vienna: Ottobock’s AxonHook & Kenevo Knee Joint

ck in Ottobo yees

emplo • 640 0 • 25,00

m2 site

Ottobock generated more than 1 billion euros in sales last year by enhancing people’s mobility. The group’s 7,600 employees successfully combine the latest technological advances with know-how about the users’ capabilities and design preferences to provide optimal solutions for each patient. Ottobock is also highly respected for its broader engagement in society, ranging from its partnership at the Paralympic Games to its Science Center in Berlin. Furthermore, Ottobock together with Össur, has established a Research Trust Fund at the University of Iceland that awards international grants for scientific research and innovative projects in the field of advanced neural control of prosthetic limbs.

© Ottobock

Award-winning idea

LISAvienna Life Science Austria Vienna Walcherstrasse 11A 1020 Vienna, Austria

PHONE FAX E-MAIL WEB

In Vienna, Ottobock has also recently developed a new flagship for its line of upper limb prosthetics: the AxonHook. Enthusiastic cooks, gardeners, and do-it-yourselfers who enjoy a variety of technical tasks will all profit from this perfect companion to the Michelangelo Hand. The innovative AxonBus system allows an easy switch to AxonHook whenever users need more versatility, precision and power. This allows talented craftspeople to continue along their life’s path.

+ 43 (0) 1 50175 358 + 43 (0) 1 50175 900 office@LISAvienna.at www.LISAvienna.at

ottobock.at

Why Vienna?

“

Hans Dietl, Chief Technology Officer at Ottobock

Our Vienna site is the locomotive for innovation in our company and one of the growth engines. Vienna provides the necessary proximity to research institutions and clinics and is an attractive location for high potentials.”

LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.

crevo.net

Extensive research on the special requirements of elderly people who use leg prosthetics led to the development of a new knee joint at Ottobock in Vienna. Kenevo offers the world’s first solution using the latest technology for the needs of people with reduced mobility. It sets a new global standard in leg prosthetics by providing security in typical everyday situations that include sitting down, standing up and walking in small and slow steps. Kenevo is able to adapt to its users’ skills, either during rehabilitation, or in cases in which mobility is decreasing. The knee joint helps to avoid stumbling and also includes a special wheelchair mode.

Ottobock recently won over the jury of the Vienna Business Agency’s R&D funding scheme “Users in Focus”. Its “Myonic” project took first place among the proposals selected for funding. New algorithms for pattern recognition combined with individual app-based training and fine-tuning are expected to further improve the steering of hand prostheses in the future.

© Ottobock / Mischa Erben

Respecting low mobility

A boon for do-it-yourselfers

© Ottobock

s

n euro 4 millio orth 11 in 2015 w ts c u • Prod ed in Vienna produc share export nt • 100 % vestme uros in e n o li il • 26 m in 2015 in R&D

Ottobock is a world-leading manufacturer and supplier of prosthetic limbs, orthotic supports and wheelchairs that facilitate independence.

In Vienna, the company’s 600 employees operate a growing R&D and manufacturing facility. A clear focus on patients’ needs guides the development of new solutions.

Ottobock’s Austrian subsidiary, Otto Bock Healthcare Products GmbH, is one of the group’s most important research and development centers, and is continuously in the process of expansion. In 2015, some 26 million euros have been invested in R&D in Vienna. Two of Ottobock’s most recent Vienna-based innovations are introduced below.

: Vienna